TICKERNERD
Menu
MYOMYOHealthcare · Medical Devices

MYO Stock Forecast: Myomo, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$1.30
0.00% on the day

The 5 Wall Street analysts covering Myomo, Inc. hold a median 12-month price target of $3 — +130.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 53 of 100 as at 11 Sept 2026 — in the upper half.

Market cap
$51.5M
Ticker Nerd rank
53 / 100
Median analyst target
$3.00
Analysts covering
5
Revenue$11.7M+21.3% y/y
Operating income−$2.3M
Net income−$4.0M
Free cash flow−$2.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−7.1%
1M
−13.9%
YTD
+42.9%
1Y
+44.6%
From 52W high
−30.1%
From 52W low
+103.1%
$0.64
$1.86
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MYO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Myomo, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 11 Sept 2026
53 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
88
Size
82
Revisions
76
Quality
74
Value
46
Growth
29
Momentum
26
Issuance
10
Volatility
10

Accruals (88): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (10): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MYO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MYO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00Oct 25Jan 26Apr 26Jul 26MYOHigh $10.50Median $3.00Low $1.70

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $1.70Median $3.00High $10.50

The green dot is the last close — the median target sits +130.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
27 Aug 2026Ascendiant CapitalMaintainsBuy—
8 June 2026Ascendiant CapitalMaintainsBuy—
21 Nov 2025Ascendiant CapitalMaintainsBuy—
22 Sept 2025Ascendiant CapitalMaintainsBuy—
12 Aug 2025HC Wainwright & Co.MaintainsBuy—
23 June 2025Craig-HallumMaintainsBuy—
5 June 2025Ascendiant CapitalMaintainsBuy—
8 May 2025Craig-HallumMaintainsBuy—
17 Mar 2025Ascendiant CapitalMaintainsBuy—
12 Mar 2025HC Wainwright & Co.MaintainsBuy—
11 Mar 2025Craig-HallumMaintainsBuy—
13 Dec 2024Craig-HallumMaintainsBuy—
13 Nov 2024HC Wainwright & Co.ReiteratesBuy$7.50
12 Nov 2024Ascendiant CapitalMaintainsBuy—
19 Aug 2024Ascendiant CapitalMaintainsBuy—
12 Aug 2024HC Wainwright & Co.MaintainsBuy—
31 July 2024Craig-HallumInitiatesBuy—
9 July 2024Lake StreetMaintainsBuy—
9 May 2024HC Wainwright & Co.ReiteratesBuy—
15 Dec 2023HC Wainwright & Co.InitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MYO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

MYO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Myomo, Inc. returned +44.6% against +17.5% for the S&P 500, dividends included.

MYO vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200Oct 25Jan 26Apr 26Jul 26MYOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MYO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
1
Fundamentals

Myomo, Inc. (MYO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.5×

Cheaper than 88% of US stocks

Price / sales
1.2×

Cheaper than 65% of US stocks

Price / book
8.8×

Cheaper than 11% of US stocks

EV / EBITDA
−5.5×

Cheaper than 79% of US stocks

Growth & margins
Revenue growth (YoY)
21.3%

Higher than 70% of US stocks

Earnings growth (YoY)
21.3%

Higher than 59% of US stocks

Gross margin
72.1%

Higher than 84% of US stocks

Operating margin
−19.3%

Higher than 22% of US stocks

Net margin
−33.5%

Higher than 13% of US stocks

Returns & dividend
Return on equity
−123.8%

Higher than 11% of US stocks

Return on assets
−19.8%

Higher than 20% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Myomo, Inc. (MYO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Myomo, Inc. has a market value of $51.5M and an enterprise value of $58.1M.

  • Revenue in the twelve months to 30 June 2026: $43.3M. The latest quarter grew 21.3% year on year.

  • Net income over the same four quarters: −$14.5M, a −33.5% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.34.

  • Free cash flow in the twelve months to 30 June 2026: −$9.1M.

  • Shares outstanding: 39.5M.

  • Trailing P/E: −3.5×; forward P/E: −5.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Myomo, Inc. employs 194 people — $223K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 11 Sept 2026

Data provided by Twelve Data

Peers

MYO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
MYOMyomo, Inc.$51.5M
53
SRTSSensus Healthcare, Inc.$51.8M
51
MDAISpectral AI, Inc.$49.1M
15
XTNTXtant Medical Holdings, Inc.$48.5M
72
NNOXNano-X Imaging Ltd.$56.9M
19
COCHEnvoy Medical, Inc.$56.9M
34
BDMDBaird Medical Investment Holdings Ltd.$46.4M
19

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Myomo, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MYO news & analysis

Myomo to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Business Wire · 1 Sept 2026neutral

Myomo, Inc. announced it will participate in the H.C. Wainwright 28th Annual Global Investment Conference, being held September 14-16, 2026 at the Lotte Palace Hotel in New York. The company's President and CEO Paul Gudonis and CFO are scheduled to attend.

Why it matters — The company's attendance at a major investment conference provides an opportunity for management to present to investors and the financial community, which MYO watchers would follow.

Myomo Q2 Earnings Call Highlights

MarketBeat · 9 Aug 2026positive

Myomo reported 21% revenue growth for the second quarter of 2026. The wearable robotics company continued shifting its patient acquisition strategy toward recurring referral sources and expanded reimbursement relationships, as highlighted in its earnings call.

Why it matters — A Myomo watcher would care because continued revenue growth and a stronger recurring referral and reimbursement model signal improving commercial traction for its wearable robotics business.

Myomo, Inc. (MYO) Q2 2026 Earnings Call Transcript

Seeking Alpha · 6 Aug 2026neutral

Seeking Alpha published the transcript of Myomo, Inc.'s Q2 2026 earnings call, providing the company's discussion of its quarterly results. The item signals that the earnings call transcript is now available to investors.

Why it matters — A MYO watcher would look to this transcript for management's firsthand commentary on the company's second-quarter performance and outlook.

Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research · 6 Aug 2026positive

Myomo, Inc. reported a second-quarter loss of $0.07 per share, which was narrower than the Zacks Consensus Estimate of a $0.10 loss and better than the $0.11 loss a year earlier. The company also topped revenue estimates for the quarter.

Why it matters — MYO watchers would care because the results came in better than consensus expectations on both the loss and revenue side, signaling improved performance relative to forecasts.

Myomo Reports Second Quarter 2026 Financial and Operating Results

Business Wire · 5 Aug 2026positive

Myomo reported its financial results for the three and six months ended June 30, 2026. The company said its evolving go-to-market approach is driving positive results, with revenue of $11.7 million exceeding expectations, with 53% of that figure not fully described in the excerpt.

Why it matters — A MYO watcher would note that the company's reported revenue exceeded its expectations, signaling that changes to its go-to-market strategy are producing positive outcomes in the quarter.

FAQ

Frequently asked questions about MYO stock

What is the MYO stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Myomo, Inc. have a median 12-month price target of $3, with estimates ranging from $1.7 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MYO stock a buy right now?

Of the 5 analysts covering Myomo, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Myomo, Inc. 53 out of 100 across roughly 4,600 US stocks as at 11 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MYO?

As at 11 Sept 2026, Myomo, Inc. ranks 53 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (88 of 100).

Will MYO stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +130.8% from the last close, and Ticker Nerd's factor model ranks Myomo, Inc. 53 out of 100 as at 11 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MYO stock forecast for 2030?

No analyst covering Myomo, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MYO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.7 to $11 over the next 12 months.

How has MYO stock performed over the past year?

Myomo, Inc. returned +44.6% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Myomo, Inc. do?

Myomo Inc. is a medical robotics company that develops and markets myoelectric orthotic devices for people with neuromuscular disorders and upper-limb paralysis.

What is the latest news on MYO?

The most recent item we track (Business Wire, 1 Sept 2026): "Myomo to Present at the H.C. Wainwright 28th Annual Global Investment Conference". Myomo, Inc. announced it will participate in the H.C. Wainwright 28th Annual Global Investment Conference, being held September 14-16, 2026 at the Lotte Palace Hotel in New York. The company's President and CEO Paul Gudonis and CFO are scheduled to attend.

Company

About Myomo, Inc.

Myomo Inc. is a medical robotics company that develops and markets myoelectric orthotic devices for people with neuromuscular disorders and upper-limb paralysis. Its flagship MyoPro product line is a powered arm brace designed to support weakened or paralyzed arms and hands by detecting the user’s own muscle signals through non-invasive sensors. The company serves patients recovering from or living with conditions such as stroke, spinal cord injury, brachial plexus injury, traumatic brain injury, ALS, and multiple sclerosis. Myomo Inc. sells its devices through orthotics and prosthetics providers, direct clinical and insurance-based channels, the Veterans Administration, and selected distributors in the United States and international markets. The company focuses on restoring upper-limb function, supporting daily activities, and improving mobility for individuals with neurological and muscular impairments.

CEO Mr. Paul R. Gudonis · 194 employees · United States · https://myomo.com